1,030 Shares of IDEXX Laboratories, Inc. $IDXX Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 1,030 shares of the company’s stock, valued at approximately $538,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Aurora Investment Managers LLC. bought a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $2,442,000. National Pension Service increased its stake in shares of IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after purchasing an additional 6,885 shares in the last quarter. NewEdge Advisors LLC increased its holdings in shares of IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after acquiring an additional 5,761 shares in the last quarter. Arizona State Retirement System increased its stake in IDEXX Laboratories by 4.9% during the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after purchasing an additional 1,074 shares in the last quarter. Finally, SVB Wealth LLC raised its holdings in IDEXX Laboratories by 17.4% in the 1st quarter. SVB Wealth LLC now owns 7,335 shares of the company’s stock worth $4,121,000 after acquiring an additional 1,089 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IDXX. KeyCorp began coverage on shares of IDEXX Laboratories in a report on Monday. They set a “sector weight” rating on the stock. Citigroup increased their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, UBS Group increased their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Trading Up 2.4%

Shares of NASDAQ IDXX opened at $560.36 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The company has a market cap of $44.15 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.92 and a beta of 1.55. The business’s 50 day moving average price is $534.22 and its 200-day moving average price is $551.84. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.80 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.